Literature DB >> 9508301

Clinical comparison of an enhanced-sensitivity branched-DNA assay and reverse transcription-PCR for quantitation of human immunodeficiency virus type 1 RNA in plasma.

F S Nolte1, J Boysza, C Thurmond, W S Clark, J L Lennox.   

Abstract

The performance characteristics of an enhanced-sensitivity branched-DNA assay (bDNA) (Quantiplex HIV-1 version 2.0; Chiron Corp., Emeryville, Calif.) and a reverse transcription (RT)-PCR assay (AMPLICOR HIV-1 Monitor; Roche Diagnostic Systems, Inc., Branchburg, N.J.) were compared in a molecular diagnostic laboratory. Samples used in this evaluation included linearity and reproducibility panels made by dilution of a human immunodeficiency virus type 1 (HIV-1) stock culture of known virus particle count in HIV-1-negative plasma, a subtype panel consisting of HIV-1 subtypes A through F at a standardized level, and 64 baseline plasma specimens from HIV-1-infected individuals. Plots of log10 HIV RNA copies per milliliter versus log10 nominal virus particles per milliliter demonstrated that both assays were linear over the stated dynamic ranges (bDNA, r = 0.98; RT-PCR, r = 0.99), but comparison of the slopes of the regression lines (bDNA, m = 0.96; RT-PCR, m = 0.83) suggested that RT-PCR had greater proportional systematic error. The between-run coefficients of variation for bDNA and RT-PCR were 24.3 and 34.3%, respectively, for a sample containing 1,650 nominal virus particles/ml and 44.0 and 42.7%, respectively, for a sample containing 165 nominal virus particles/ml. Subtypes B, C, and D were quantitated with similar efficiencies by bDNA and RT-PCR; however, RT-PCR was less efficient in quantitating subtypes A, E, and F. One non-B subtype was recognized in our clinical specimens based on the ratio of values obtained with the two methods. HIV-1 RNA was quantitated in 53 (83%) baseline plasma specimens by bDNA and in 55 (86%) specimens by RT-PCR. RT-PCR values were consistently greater than bDNA values, with population means of 142,419 and 67,580 copies/ml, respectively (P < 0.01). The results were highly correlated (r = 0.91), but the agreement was poor (mean difference in log10 copies per milliliter +/- 2 standard deviations, 0.45 +/- 0.61) for the 50 clinical specimens that gave discrete values with both methods.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9508301      PMCID: PMC104614          DOI: 10.1128/JCM.36.3.716-720.1998

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  20 in total

Review 1.  HIV viral load markers in clinical practice.

Authors:  M S Saag; M Holodniy; D R Kuritzkes; W A O'Brien; R Coombs; M E Poscher; D M Jacobsen; G M Shaw; D D Richman; P A Volberding
Journal:  Nat Med       Date:  1996-06       Impact factor: 53.440

2.  Comparative evaluation of NASBA HIV-1 RNA QT, AMPLICOR-HIV monitor, and QUANTIPLEX HIV RNA assay, three methods for quantification of human immunodeficiency virus type 1 RNA in plasma.

Authors:  H Revets; D Marissens; S de Wit; P Lacor; N Clumeck; S Lauwers; G Zissis
Journal:  J Clin Microbiol       Date:  1996-05       Impact factor: 5.948

Review 3.  Correlation between viral load measurements and outcome in clinical trials of antiviral drugs.

Authors:  R T Schooley
Journal:  AIDS       Date:  1995-12       Impact factor: 4.177

4.  Statistical methods for assessing agreement between two methods of clinical measurement.

Authors:  J M Bland; D G Altman
Journal:  Lancet       Date:  1986-02-08       Impact factor: 79.321

5.  Genetic diversity and HIV detection by PCR.

Authors:  J P Clewley
Journal:  Lancet       Date:  1995-12-02       Impact factor: 79.321

6.  Genetic diversity and HIV detection by polymerase chain reaction.

Authors:  I Loussert-Ajaka; D Descamps; F Simon; F Brun-Vézinet; M Ekwalanga; S Saragosti
Journal:  Lancet       Date:  1995-09-30       Impact factor: 79.321

7.  HIV quantification: clinical applications.

Authors:  P A Volberding
Journal:  Lancet       Date:  1996-01-13       Impact factor: 79.321

8.  Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: application to acute retroviral infection.

Authors:  J Mulder; N McKinney; C Christopherson; J Sninsky; L Greenfield; S Kwok
Journal:  J Clin Microbiol       Date:  1994-02       Impact factor: 5.948

Review 9.  Human immunodeficiency virus (HIV) RNA in plasma as the preferred target for therapy in patients with HIV infection: a critique.

Authors:  W J Fessel
Journal:  Clin Infect Dis       Date:  1997-02       Impact factor: 9.079

10.  Prognosis in HIV-1 infection predicted by the quantity of virus in plasma.

Authors:  J W Mellors; C R Rinaldo; P Gupta; R M White; J A Todd; L A Kingsley
Journal:  Science       Date:  1996-05-24       Impact factor: 47.728

View more
  27 in total

1.  Comparative evaluation of two branched-DNA human immunodeficiency virus type 1 RNA quantification assays with lower detection limits of 50 and 500 copies per milliliter.

Authors:  C Manegold; C Krempe; H Jablonowski; L Kajala; M Dietrich; O Adams
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

Review 2.  The role of DNA amplification technology in the diagnosis of infectious diseases.

Authors:  M Louie; L Louie; A E Simor
Journal:  CMAJ       Date:  2000-08-08       Impact factor: 8.262

3.  Assessment of agreement between the AMPLICOR HIV-1 MONITOR test versions 1.0 and 1.5.

Authors:  Charles E Hill; Alicia M Green; Jessica Ingersoll; Kirk A Easley; Frederick S Nolte; Angela M Caliendo
Journal:  J Clin Microbiol       Date:  2004-01       Impact factor: 5.948

4.  Transcriptional profiling of TLR-4/7/8-stimulated guinea pig splenocytes and whole blood by bDNA assay.

Authors:  Lance K Ching; Farah Mompoint; Jeffrey A Guderian; Alex Picone; Ian M Orme; Rhea N Coler; Steven G Reed; Susan L Baldwin
Journal:  J Immunol Methods       Date:  2011-08-03       Impact factor: 2.303

5.  Intra- and interlaboratory variabilities of results obtained with the Quantiplex human immunodeficiency virus type 1 RNA bDNA assay, version 3.0.

Authors:  J A Kellogg; P V Atria; J C Sanders; M E Eyster
Journal:  Clin Diagn Lab Immunol       Date:  2001-05

6.  One-tube real-time isothermal amplification assay to identify and distinguish human immunodeficiency virus type 1 subtypes A, B, and C and circulating recombinant forms AE and AG.

Authors:  M P de Baar; E C Timmermans; M Bakker; E de Rooij; B van Gemen; J Goudsmit
Journal:  J Clin Microbiol       Date:  2001-05       Impact factor: 5.948

7.  Evaluation of performance of the Gen-Probe human immunodeficiency virus type 1 viral load assay using primary subtype A, C, and D isolates from Kenya.

Authors:  S Emery; S Bodrug; B A Richardson; C Giachetti; M A Bott; D Panteleeff; L L Jagodzinski; N L Michael; R Nduati; J Bwayo; J K Kreiss; J Overbaugh
Journal:  J Clin Microbiol       Date:  2000-07       Impact factor: 5.948

Review 8.  Application of nucleic acid amplification in clinical microbiology.

Authors:  G Lisby
Journal:  Mol Biotechnol       Date:  1999-08       Impact factor: 2.695

9.  Use of real-time polymerase chain reaction to identify cell- and tissue-type-selective peptides by phage display.

Authors:  David L Jaye; Frederick S Nolte; Luca Mazzucchelli; Cissy Geigerman; Adil Akyildiz; Charles A Parkos
Journal:  Am J Pathol       Date:  2003-05       Impact factor: 4.307

10.  Evaluation of the ultrasensitive Roche Amplicor HIV-1 monitor assay for quantitation of human immunodeficiency virus type 1 RNA.

Authors:  M Erali; D R Hillyard
Journal:  J Clin Microbiol       Date:  1999-03       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.